CA3157686A1 - Analgesic and anesthetic peptides and other agents - Google Patents

Analgesic and anesthetic peptides and other agents

Info

Publication number
CA3157686A1
CA3157686A1 CA3157686A CA3157686A CA3157686A1 CA 3157686 A1 CA3157686 A1 CA 3157686A1 CA 3157686 A CA3157686 A CA 3157686A CA 3157686 A CA3157686 A CA 3157686A CA 3157686 A1 CA3157686 A1 CA 3157686A1
Authority
CA
Canada
Prior art keywords
peptide
pain
ap2a2
injection
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157686A
Other languages
English (en)
French (fr)
Inventor
Arindam Bhattacharjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CA3157686A1 publication Critical patent/CA3157686A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3157686A 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents Pending CA3157686A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913512P 2019-10-10 2019-10-10
US62/913,512 2019-10-10
PCT/US2020/055289 WO2021072392A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Publications (1)

Publication Number Publication Date
CA3157686A1 true CA3157686A1 (en) 2021-04-15

Family

ID=75437541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157686A Pending CA3157686A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Country Status (10)

Country Link
US (1) US20240294571A1 (enExample)
EP (1) EP4051690A4 (enExample)
JP (1) JP2022551467A (enExample)
KR (1) KR20220079651A (enExample)
CN (1) CN114829372A (enExample)
AU (1) AU2020364246A1 (enExample)
BR (1) BR112022006862A2 (enExample)
CA (1) CA3157686A1 (enExample)
IL (1) IL292102A (enExample)
WO (1) WO2021072392A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029752A2 (en) * 2023-07-28 2025-02-06 Gate Science, Inc. Methods and systems for pain management and testing thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
KR20030069989A (ko) * 2000-09-08 2003-08-27 다이이찌 산토리 파마 가부시키가이샤 심부전 치료제
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
WO2012019192A2 (en) * 2010-08-06 2012-02-09 Mount Sinai School Of Medicine Cell-permeable molecules as growth factor receptor antagonists
CN111712252A (zh) * 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途

Also Published As

Publication number Publication date
CN114829372A (zh) 2022-07-29
JP2022551467A (ja) 2022-12-09
AU2020364246A1 (en) 2022-05-12
US20240294571A1 (en) 2024-09-05
KR20220079651A (ko) 2022-06-13
IL292102A (en) 2022-06-01
WO2021072392A1 (en) 2021-04-15
BR112022006862A2 (pt) 2022-07-05
EP4051690A1 (en) 2022-09-07
EP4051690A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
Walrave et al. I nhibition of astroglial connexin43 hemichannels with TAT‐G ap19 exerts anticonvulsant effects in rodents
Bourinet et al. Silencing of the Cav3. 2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception
Powell et al. Inhibiting endocytosis in CGRP+ nociceptors attenuates inflammatory pain-like behavior
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
AU2025271034A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
James et al. Pharmacotherapy of painful diabetic neuropathy: a clinical update
Jiang et al. Cardiac-specific overexpression of Claudin-5 exerts protection against myocardial ischemia and reperfusion injury
US11365413B2 (en) Inhibition of poly(A) binding protein and the treatment of pain
Lopes et al. Maresin-2 inhibits inflammatory and neuropathic trigeminal pain and reduces neuronal activation in the trigeminal ganglion
JP2019522989A (ja) ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
CN105848720A (zh) 用于诱导葡萄糖摄取的方法
US20240294571A1 (en) Analgesic and anesthetic peptides and other agents
WO2011148200A1 (en) Treatment of pain
US9993522B2 (en) Treatment of pain by inhibition of USP5 de-ubiquitinase
Li et al. Netrin-1 contributes to peripheral nerve injury induced neuropathic pain via regulating phosphatidylinositol 4-kinase IIa in the spinal cord dorsal horn in mice
KR20130027016A (ko) 포유류와 인간 세포에서 ｈｉｖ 복제를 억제하는 방법
Lai et al. CtBP1 is essential for epigenetic silencing of μ-opioid receptor genes in the dorsal root ganglion in spinal nerve ligation-induced neuropathic pain
US10851378B2 (en) Methods of treating pain using anti-GPR160 antibodies
US20100292454A1 (en) Neuronal regeneration promoting agent
US20250064846A1 (en) Treatment and prevention of trigeminal neuralgia
AU2019325622C1 (en) Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
Powell II Nociceptor Endocytosis Regulates Inflammatory Pain
CN121695274A (zh) 抑郁症的治疗方法和药物组合物
Thakor Development of a novel sensory neuron gene delivery platform with concomitant investigation of messenger ribonucleic acid translocation for the NaV1. 8 sodium channel during neuropathic pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240925

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241008

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241008

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241114

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241114

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250711

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125